Observed rates of culture positivity at month 2 (center columns) and predicted rates of relapse (right columns) based on data from five 2-month trials of experimental moxifloxacin-containing regimens.

Relapse rates were predicted using the equation parameters in table 2. Treatment durations of 4 and 5 months were considered for the moxifloxacin regimens; a duration of 6 months was assumed for standard (HRZE) treatment. Parentheses indicate 80% prediction intervals for a trial with 680 subjects per arm. Findings from 4 of the 5 studies could be considered as supporting a role for moxifloxacin in 5 month regimens; however, none supported a role as a 4 month regimen, due to increased relapse risk.